Drug-induced liver injury due to varenicline: a case report
<p>Abstract</p> <p>Background</p> <p>Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-06-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-230X/12/65 |
| _version_ | 1818806107389296640 |
|---|---|
| author | Sprague David Bambha Kiran |
| author_facet | Sprague David Bambha Kiran |
| author_sort | Sprague David |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the Food and Drug Administration against certain medications and supplements.</p> <p>Case presentation</p> <p>A 69-year-old Latino man was referred to Hepatology Clinic for urgent evaluation of new onset jaundice, nausea and fatigue associated with a >40-fold increase in his transaminase levels and elevated INR and alkaline phosphatase. The patient had received a new prescription for varenicline to aid with smoking cessation approximately 3 weeks prior to his evaluation in Hepatology Clinic. Within 5 days of starting the varenicline, the patient developed new onset of nausea, vomiting, malaise and deep jaundice. The varenicline was discontinued on day 5 by the patient. Hepatologic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic or alcohol-related liver disorders. The patient’s past medical history was notable, however, for chronic hepatitis C. His liver enzymes and synthetic function completely normalized 9 weeks after discontinuation of the varenicline.</p> <p>Conclusion</p> <p>This report represents the second documented cases of drug-induced liver injury related to varenicline therapy, highlighting the need for clinician awareness regarding potential hepatotoxicity of varenicline, particularly among patients with pre-existing liver disease.</p> |
| first_indexed | 2024-12-18T19:04:31Z |
| format | Article |
| id | doaj.art-6d20498b08a24300b8ea9ef862b71c4b |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-18T19:04:31Z |
| publishDate | 2012-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-6d20498b08a24300b8ea9ef862b71c4b2022-12-21T20:56:26ZengBMCBMC Gastroenterology1471-230X2012-06-011216510.1186/1471-230X-12-65Drug-induced liver injury due to varenicline: a case reportSprague DavidBambha Kiran<p>Abstract</p> <p>Background</p> <p>Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the Food and Drug Administration against certain medications and supplements.</p> <p>Case presentation</p> <p>A 69-year-old Latino man was referred to Hepatology Clinic for urgent evaluation of new onset jaundice, nausea and fatigue associated with a >40-fold increase in his transaminase levels and elevated INR and alkaline phosphatase. The patient had received a new prescription for varenicline to aid with smoking cessation approximately 3 weeks prior to his evaluation in Hepatology Clinic. Within 5 days of starting the varenicline, the patient developed new onset of nausea, vomiting, malaise and deep jaundice. The varenicline was discontinued on day 5 by the patient. Hepatologic evaluation revealed no evidence of acute viral hepatitis, autoimmune, metabolic or alcohol-related liver disorders. The patient’s past medical history was notable, however, for chronic hepatitis C. His liver enzymes and synthetic function completely normalized 9 weeks after discontinuation of the varenicline.</p> <p>Conclusion</p> <p>This report represents the second documented cases of drug-induced liver injury related to varenicline therapy, highlighting the need for clinician awareness regarding potential hepatotoxicity of varenicline, particularly among patients with pre-existing liver disease.</p>http://www.biomedcentral.com/1471-230X/12/65Drug induced liver injuryVareniclineIdiosyncratic |
| spellingShingle | Sprague David Bambha Kiran Drug-induced liver injury due to varenicline: a case report BMC Gastroenterology Drug induced liver injury Varenicline Idiosyncratic |
| title | Drug-induced liver injury due to varenicline: a case report |
| title_full | Drug-induced liver injury due to varenicline: a case report |
| title_fullStr | Drug-induced liver injury due to varenicline: a case report |
| title_full_unstemmed | Drug-induced liver injury due to varenicline: a case report |
| title_short | Drug-induced liver injury due to varenicline: a case report |
| title_sort | drug induced liver injury due to varenicline a case report |
| topic | Drug induced liver injury Varenicline Idiosyncratic |
| url | http://www.biomedcentral.com/1471-230X/12/65 |
| work_keys_str_mv | AT spraguedavid druginducedliverinjuryduetovareniclineacasereport AT bambhakiran druginducedliverinjuryduetovareniclineacasereport |